Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma

Published:2018-03-20 Issue:8 Volume:118 Page:1051-1055
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ma Brigette,Hui Edwin P,King Ann^ORCID,Leung Sing F,Kam Michael KM,Mo Frankie,Li Leung,Wang Ki,Loong Herbert,Wong Ashley,Chan Charles ML,Chan KC Allen,Wong SC Cesar,Lo YM Dennis,Chan Anthony TC

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0026-9.pdf

Reference24 articles.

1. Lee, A. W., Ma, B. B., Ng, W. T. & Chan, A. T. Management of nasopharyngeal carcinoma: current practice and future perspective. J. Clin. Oncol. 33, 3356–3364 (2015).

2. Cao, S. M. et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur. J. Cancer 75, 14–23 (2017).

3. Sun, Y. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17, 1509–1520 (2016).

4. Hui, E. P. et al. Randomised phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27, 242–249 (2009).

5. Lee, A. W. et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 121, 1328–1338 (2015b).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III‐IVa nasopharyngeal carcinoma: A real‐world study based on medical comorbidities;Head & Neck;2024-02-17

2. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors;International Forum of Allergy & Rhinology;2024-01-02

3. Pretreatment dual-energy CT for predicting early response to induction chemotherapy and survival in nasopharyngeal carcinoma;European Radiology;2023-07-05

4. Progress in the comprehensive treatment of nasopharyngeal carcinoma: a review for risk-stratified management strategies;Holistic Integrative Oncology;2023-07-03

5. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?;Current Treatment Options in Oncology;2023-06-15